Relatório global de análise de tamanho, participação e análise de tendências do mercado de testes de infeções virais transmitidas por artrópodes – Visão geral do setor e previsão para 2031

Análise de mercado de testes de infeções virais transmitidas por artrópodes

À medida que a incidência global destas infecções aumenta devido a factores como as alterações climáticas, a urbanização e as viagens internacionais, a procura por soluções de testes rápidas e precisas aumentou. O mercado apresenta diversas ferramentas de diagnóstico , incluindo testes moleculares, imunoensaios e métodos culturais. Os avanços recentes incluem o desenvolvimento de testes moleculares mais sensíveis e portáteis. Além disso, as colaborações entre as agências de saúde pública e as empresas de diagnóstico visam melhorar as capacidades de resposta globais, aumentando o crescimento do mercado.

Tamanho do mercado de testes de infeções virais transmitidas por artrópodes

A dimensão global do mercado de testes de infeções virais transmitidas por artrópodes foi avaliada em 1,14 mil milhões de dólares em 2023 e deverá atingir 1,77 mil milhões de dólares até 2031, com um CAGR de 5,65% durante o período de previsão de 2024 a 2031. Para além dos insights sobre os cenários de mercado, tais como o valor de mercado, a taxa de crescimento, a segmentação, a cobertura geográfica e os grandes players, os relatórios de mercado com curadoria da Data Bridge Market Research incluem também a análise especializada aprofundada, a epidemiologia dos doentes, análise de pipeline, análise de preços e enquadramento regulamentar.

Tendências do mercado de testes de infeções virais transmitidas por artrópodes

“ Inovações nas tecnologias de diagnóstico”

As inovações nas tecnologias de diagnóstico, como os testes moleculares e os imunoensaios no local de atendimento, estão a transformar o mercado, oferecendo uma deteção mais rápida e precisa destas infeções. Uma tendência importante é a mudança para diagnósticos rápidos e portáteis, permitindo aos prestadores de cuidados de saúde diagnosticar rapidamente os doentes em áreas remotas ou propensas a surtos. Estes avanços estão a melhorar a deteção precoce e a gestão de infeções virais, reduzindo a propagação de doenças. À medida que crescem as preocupações globais com a saúde pública, a procura por soluções de testes avançadas e fáceis de utilizar continua a aumentar, tornando esta uma área crítica de foco no setor dos diagnósticos de saúde.

Âmbito do relatório e segmentação do mercado de testes de infeções virais transmitidas por artrópodes

Arthropod-Borne Viral Infections Testing Market Definition

Arthropod-Borne Viral Infections Testing refers to the diagnostic processes used to detect viruses transmitted by arthropods, such as mosquitoes, ticks, and fleas. These viruses, including dengue, Zika, chikungunya, and West Nile, cause diseases that can lead to severe health complications. Testing methods include molecular tests, immunoassays, and culture-based approaches, which help in the timely identification and management of these infections to prevent outbreaks and ensure appropriate treatment.

Arthropod-Borne Viral Infections Testing Market Dynamics

Drivers

• Rising Prevalence of Arthropod-Borne Diseases

The increasing incidence of arthropod-borne diseases such as dengue, Zika, chikungunya, and West Nile virus significantly drives the demand for advanced testing solutions. These viral infections, transmitted primarily through mosquitoes, have seen a notable rise in global cases due to factors such as climate change, urbanization, and increased travel. For instance, dengue cases have surged dramatically in tropical and subtropical regions, prompting urgent healthcare responses. Consequently, there is a pressing need for efficient and reliable diagnostic methods to facilitate early detection and management of these diseases, ultimately enhancing patient outcomes and public health initiatives. This trend underscores the critical need for innovative testing solutions in the market.

• Advancements in Molecular Diagnostic Technologies

Advancements in molecular diagnostic technologies, including polymerase chain reaction (PCR) and next-generation sequencing (NGS), are pivotal in driving growth in the arthropod-borne viral infections testing market. These technologies allow for rapid and precise detection of viral pathogens, significantly enhancing diagnostic accuracy. PCR techniques can identify specific genetic material of viruses within hours, while NGS provides comprehensive genomic data, facilitating the understanding of viral mutations and epidemiology. As healthcare providers increasingly adopt these innovative testing solutions, they can respond more effectively to outbreaks and manage patient care, ultimately propelling the demand for molecular diagnostics in this critical sector of infectious disease testing.

Opportunities

• Telemedicine and Remote Testing Solutions

The rise of telemedicine and remote patient monitoring presents a significant opportunity for the arthropod-borne viral infections testing market, particularly through the development and distribution of at-home testing kits. These kits allow individuals in underserved regions to access diagnostic solutions conveniently, eliminating the barriers posed by distance and healthcare accessibility. As telehealth continues to grow, patients can conduct tests in the comfort of their homes and receive results quickly, facilitating timely medical intervention. This shift enhances patient engagement and reduces the burden on healthcare facilities, driving demand for innovative testing products tailored for remote use in the management of viral infections.

• Vaccine Development and Monitoring

The development of new vaccines for arthropod-borne diseases presents a significant market opportunity for specialized diagnostic solutions focused on efficacy and safety testing. As public health initiatives strive to combat viral infections such as dengue and Zika, the demand for comprehensive testing methods becomes essential to ensure vaccine performance and patient safety. Diagnostic tools that can accurately assess immune responses and identify adverse effects will be crucial in evaluating vaccine candidates during clinical trials and post-marketing surveillance. This need for rigorous testing supports vaccine development and fosters innovation in the diagnostics sector, driving growth and investment in cutting-edge testing technologies.

Restraints/Challenges

• High Cost of Molecular Diagnostic Technologies

The high costs associated with the development and implementation of advanced molecular diagnostic technologies, such as polymerase chain reaction (PCR) and next-generation sequencing (NGS), pose a significant challenge in the arthropod-borne viral infections testing market. These sophisticated technologies require substantial investment in equipment, reagents, and training, making them less accessible for smaller laboratories and healthcare providers, especially in low-resource settings. This financial barrier can lead to disparities in diagnostic capabilities, limiting timely and accurate testing in regions most affected by arthropod-borne diseases. Consequently, this challenge hampers effective disease management and control efforts, highlighting the need for more affordable and accessible testing solutions.

• Inconsistent Disease Surveillance

Variability in disease surveillance systems poses a significant restraint on the arthropod-borne viral infections testing market, as it can lead to incomplete and inconsistent data regarding infection prevalence. In many regions, particularly in low-resource settings, surveillance efforts may be underfunded or poorly organized, resulting in gaps in information about disease outbreaks and transmission patterns. This lack of reliable data can hinder effective public health responses, as decision-makers rely on accurate statistics to allocate resources and implement control measures. Consequently, the uncertainty in disease prevalence diminishes the perceived need for testing, negatively impacting market demand and stifling advancements in diagnostic capabilities.

This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Arthropod-Borne Viral Infections Testing Market Scope

The market is segmented on the basis of test type and end-user. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Test Type

• Molecular Tests
• Cultural Tests
• Immunoassays
• Others

End User

• Hospitals
• Research Centers
• Diagnostic Centers

Arthropod-Borne Viral Infections Testing Market Regional Analysis

The market is analysed and market size insights and trends are provided by country, test type, and end-user as referenced above.

The countries covered in the market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the arthropod-borne viral infections testing market, driven by the swift advancement of diagnostic technologies in the region. The integration of innovative solutions, such as PCR and next-generation sequencing, enhances testing accuracy and efficiency. Furthermore, robust healthcare infrastructure and substantial investment in research contribute to the region's leadership in this market.

The Asia-Pacific region is projected to experience substantial growth in the arthropod-borne viral infections testing market from 2024 to 2031, primarily due to its large population at risk for infections. The high prevalence of arboviruses in this area further exacerbates the demand for effective diagnostic solutions. Additionally, increasing public health awareness and improved healthcare infrastructure are likely to drive this market expansion in the coming years.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.  

Arthropod-Borne Viral Infections Testing Market Share

The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.

Arthropod-Borne Viral Infections Testing Market Leaders Operating in the Market Are:

• Thermo Fisher Scientific, Inc. (U.S.)
• BioMérieux (France)
• Hologic, Inc. (U.S.)
• EUROIMMUN Medizinische Labordiagnostika AG (Germany)
• Bio-Rad Laboratories, Inc. (U.S.)
• F. Hoffmann-La Roche Ltd (Switzerland)
• InBios International Inc. (U.S.)
• Quest Diagnostics Incorporated (EUA)
• CERTEST BIOTEC (Espanha)
• Resposta Biomédica (Canadá)
• Chembio Diagnostics, Inc.
• Abbott (EUA)

Últimos desenvolvimentos no mercado de testes de infeções virais transmitidas por artrópodes

• Em Maio de 2024, o Fundo Global de Tecnologia Inovadora em Saúde (GHIT) anunciou um investimento de aproximadamente 1,64 mil milhões de ienes (10,8 milhões de dólares) destinado a avançar quatro projectos centrados no desenvolvimento de novos tratamentos para a malária e doenças tropicais negligenciadas. Esta iniciativa de financiamento destaca o compromisso da organização em enfrentar os desafios críticos de saúde em regiões desfavorecidas. Ao apoiar o desenvolvimento de medicamentos inovadores, o GHIT visa melhorar as opções terapêuticas e melhorar os resultados de saúde das populações afetadas em todo o mundo.
• Em maio de 2023, a Astellas Pharma Inc. anunciou o seu compromisso com o Fundo Global de Tecnologia Inovadora em Saúde, que visa apoiar o desenvolvimento de medicamentos, ferramentas de diagnóstico e vacinas destinadas a combater diversas doenças infeciosas. Esta contribuição centra-se particularmente nas doenças tropicais sub-reconhecidas que, muitas vezes, carecem de financiamento e recursos suficientes. Ao investir nesta iniciativa, a Astellas Pharma procura melhorar os resultados globais em matéria de saúde e colmatar lacunas críticas na gestão de doenças infeciosas
• Em julho de 2022, a Mylab Discovery Solutions apresentou o seu inovador kit de teste de doenças, o ‘PathoDetect Extended Monsoon Fever Panel’, que apresentava uma sensibilidade e especificidade impressionantes. Este painel avançado diferencia eficazmente entre diversas doenças infeciosas, incluindo a malária, chikungunya, dengue, zika, leptospirose, espécies bacterianas de salmonelose e o parasita leishmaniose. Com a sua capacidade de identificar com precisão múltiplos agentes patogénicos, este kit de teste melhora as capacidades de diagnóstico durante a estação das monções, abordando os desafios críticos de saúde nas regiões afetadas
• Em novembro de 2021, a Achico, uma empresa suíça de tecnologia de saúde, anunciou o desenvolvimento de kits de diagnóstico específicos para a dengue. Estes kits de teste inovadores aproveitam a plataforma tecnológica de aptâmeros de ADN da empresa, que se mostrou eficaz no diagnóstico da COVID-19. Ao aplicar esta tecnologia avançada ao diagnóstico da dengue, a Achico pretende aumentar a precisão e a eficiência dos testes para esta importante doença infecciosa
• Em novembro de 2021, a empresa suíça de tecnologia de saúde Achico revelou os seus planos para desenvolver kits de diagnóstico para a dengue. Estes kits de teste inovadores utilizarão a plataforma tecnológica de aptâmeros de ADN da empresa, que já demonstrou a sua eficácia no diagnóstico da COVID-19. Este avanço visa melhorar as capacidades de diagnóstico da dengue, atendendo à crescente necessidade de soluções de testes fiáveis.

SKU-63602